CONCORDBIO1,445.20

Concord Biotech Ltd.

· Pharma & Health
₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹15,119 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)411.32330.97468.33468.33
Receivable Days (DSO)125.48158.66159.23159.23
Payable Days (DPO)186.79156.10146.24140.74
Cash Conversion Cycle (days)350.01333.53481.32486.82
Working Capital Turnover1.351.260.981.03
Asset Turnover0.600.590.470.47
Cash Conversion (CFO/Net Income)0.860.661.031.03
CFO/EBITDA0.620.480.730.73
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.